The U.K. government created a new £21 million ($US26.55 million) fund to accelerate the roll out of artificial intelligence (AI) diagnostics and treatment tools across the NHS. The AI Diagnostic Fund will enable hospitals to bid for funding to speed up the deployment of the most promising AI imaging and decision support tools to help patients with cancers, strokes and heart conditions.
Researchers at Boehringer Ingelheim (BI) Pharma GmbH & Co. KG and Vanderbilt University have described proteolysis targeting chimera (PROTAC) compounds comprising E3 ubiquitin ligase binding moieties covalently linked to GTPase KRAS (mutant) binding moieties through a linker.
Marvel Biotechnology Inc. has divulged purine compounds acting as adenosine A2A receptor (ADORA2A) antagonists reported to be useful for the treatment of cancer, depression, anxiety disorder, multiple sclerosis, nonalcoholic steatohepatitis, scleroderma, Alzheimer’s disease and Parkinson’s disease.
Coimmune Inc. has obtained a license to target delta-like ligand 3 (DLL3) with IL-18 armored chimeric antigen receptor (CAR) technology. The company exercised an option to obtain an exclusive license in the DLL3-targeted, allogeneic CAR-cytokine induced killer (CAR-CIK) cell therapy field to IL-18 armored CAR technology under an agreement with Memorial Sloan Kettering Cancer Center (MSK).
B cells that expressed a constellation of checkpoint inhibitors could be spurred into antitumor activity by deleting or blocking the checkpoint molecule T-cell immunoglobulin and mucin domain 1 (TIM-1). The findings, which were published online in Nature on June 21, 2023, suggest ways to bring B cells into the antitumor fight. More broadly, Lloyd Bod told BioWorld, his laboratory aims to “break the dogma that B cells only produce antibodies.”
Scientists in the U.K. have reacted with dismay to the announcement that the National Cancer Research Institute (NCRI) is to close, 22 years after it was set up to coordinate the efforts of industry, government research agencies and medical charities that sponsor and fund clinical trials.
Later this year, Mendus AB plans to move its allogeneic cell-based cancer vaccine, vididencel, into a phase II combination trial with oral azacitidine to evaluate the regimen’s potential as a maintenance therapy in patients with acute myeloid leukemia (AML).
The dose-escalation portion of Black Diamond Therapeutics Inc.’s phase I study of BDTX-1535 for treating non-small-cell lung cancer (NSCLC) produced strong data that moved the market in a big way.
RSS
